Mariela R. Pow-Sang, MD, Victor Benavente, MD, Julio E. Pow-Sang, MD, Carlos Morante, MD, Luis Meza, MD, Mark Baker, MD, and Julio M. Pow-Sang, MD


Cancer Control. 2002;9(4) 

In This Article

Chemotherapy for Penile Cancer

The experience with cytotoxic drugs in penile and urethral carcinomas is limited to small series, with inconclusive results. Some response has been observed with cisplatin, bleomycin, and methotrexate, as well as with combinations of these agents.[78] Shammas et al[79] used cisplatin and 5-fluorouracil to treat 8 patients with advanced squamous cell carcinoma of the penis (Jackson stages III and IV). Two patients achieved a partial response, 1 requiring a further operation and 1 requiring surgery with radiotherapy to achieve a complete response. These 2 patients were disease-free at 32 and 57 months. Nonresponders had a survival range of 2 to 28 months after chemotherapy.[79] Kattan and associates[80] treated 14 patients with cisplatin-based chemotherapy combined with other chemotherapeutic agents. Thirteen patients were evaluable for response. Objective responses were achieved in 2 patients (15%), with 1 complete and 1 partial. There were 2 patients with long-term evidence of no disease among 12 patients with stage IV disease. These 2 patients received complementary irradiation in association with the chemotherapy. In this study, methotrexate-based regimens seemed to be most effective.[80] Pizzocaro et al[81] evaluated neoadjuvant chemotherapy with combined vincristine, bleomycin, and methotrexate in 16 patients with fixed inguinal nodes. Nine (56%) of the 16 patients underwent successful surgical resection, and 5 (31%) achieved 5-year disease-free survival. The Southwest Oncology Group[82] evaluated combination chemotherapy with cisplatin, bleomycin, and methotrexate in patients with metastatic disease. Of 40 patients evaluable for response, 5 complete responses and 8 partial responses occurred for a 32.5% response rate. The therapy was associated with excessive toxicity, with 5 treatment-related deaths. Six of the remaining patients evaluable for toxicity had 1 or more life-threatening toxic episodes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.